Precigen Gives Business Updates, Significant Progress Made In The Development Of The PRGN-2012 Adenoverse Immunotherapy For The Treatment Of RRP; Plans To Submit A BLA Under An Accelerated Approval Pathway In 2H Of 2024
Portfolio Pulse from Benzinga Newsdesk
Precigen announced significant progress in the development of PRGN-2012 AdenoVerse immunotherapy for RRP treatment, planning a BLA submission for accelerated approval in 2H 2024. The company received FDA's Breakthrough Therapy Designation for PRGN-2012 and is advancing other studies, including PRGN-2009 in combination with pembrolizumab for cervical cancer, and PRGN-3006 and PRGN-3007 UltraCAR-T therapies. Financially, Precigen reported $62.9 million in cash and investments as of December 31, 2023, and a 16% reduction in SG&A costs year-over-year.
March 19, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen progresses on PRGN-2012 for RRP treatment, plans BLA submission for 2H 2024, and reports solid financials with $62.9M in assets and reduced SG&A costs.
The announcement of significant progress in PRGN-2012's development and plans for accelerated approval submission could positively impact investor sentiment, reflecting Precigen's strong R&D capabilities and potential market expansion. The financial stability indicated by $62.9 million in assets and reduced SG&A costs further supports a positive outlook, suggesting efficient cost management and resource allocation towards high-potential projects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100